Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib or Alectinib in Truncated ALK-positive Bone Cancer
NCT07560410Phase 2Not yet recruiting
- Sponsor
- China Medical University Hospital
- Start
- May 2026
- Primary completion
- Jan 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of alectinib, crizotinib in bone cancer, sponsored by China Medical University Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
alectinibcrizotinib
03
Conditions
bone cancer
Beyond the preview
Go deeper on NCT07560410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560410.